BridgeBio Pharma Inc

The company pulled in 243.7 million dollars in the second quarter, with 222.4 million of that coming from its heart pill Attruby in the U.S. alone. Revenue is up about 126 percent over the past year. More and more doctors are starting brand new patients on it instead of the older option.

All three of the company's other medicines are now sitting with regulators, and the first decision lands November 27, 2026. It also closed a 1 billion dollar funding deal on July 1, on top of 720.2 million dollars already in the bank. That means it can launch all three without running out of money.

Even with 243.7 million dollars in quarterly revenue, the company still loses more than it earns, with net margins sitting around negative 124 percent. Developing four medicines at once is expensive, and profits are not here yet.

Roughly 91 percent of last quarter's revenue came from a single medicine. If a rival takes share or insurers push back on price, there is no second product big enough to cover the gap until the next approvals arrive in late 2026 and beyond.